Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of Significant Customer's Revenues and Account Receivable Percentage

Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended March 31, 2022 and 2021 consist of the following:

	CUSTOMER
	A			B			C			D
Three months ended March 31,
2022		22	%		22	%		11	%		9	%
2021		16	%		30	%		4	%		11	%

Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either March 31, 2022 or December 31, 2021, which may or may not correspond with any of the customers above, consist of the following:

	CUSTOMER
	A			B			C			D
March 31, 2022		24	%		19	%		13	%		4	%
December 31, 2021		7	%		39	%		13	%		10	%

Schedule of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows (in thousands):

	MARCH 31,		DECEMBER 31,
	2022		2021
Cash and cash equivalents	$	9,362	$	19,623
Restricted cash, less current portion		1,560		1,560
Total cash, cash equivalents and restricted cash	$	10,922	$	21,183

Schedule of Deferred Revenue

	MARCH 31,			DECEMBER 31,
	2022			2021
Product revenues	$	12		$	87
Financing costs		459			477
License revenues		893			961
Total deferred revenues		1,364			1,525
Less current portion		(285	)		(360	)
Long term portion	$	1,079		$	1,165

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	MARCH 31,		MARCH 31,
	2022		2021
Stock options outstanding		13,614		13,572
Warrants to purchase common stock		152		6,814
Restricted stock units outstanding		5,509		4,772
Common shares to be issued in lieu of agent fees		498		498
Employee stock purchase plan		102		84
Maximum contingent consideration shares to be issued		5,415		5,972
		25,290		31,712

MARRONE BIO INNOVATIONS INC 10-Q